Illustrative

Extension of Lecanemab Trial Shows Continued Benefit

Neurology Today·Apr 20

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

An extension of the lecanemab trial has been conducted. The trial extension has shown continued benefit. The results of the extended trial are being reported as a continuation of the initial findings.

Full coverage

Updates on Blarcamesine and Lecanemab for Alzheimer Disease From AD/PD 2026

Psychiatric Times·Mar 24

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

Eisai·Jul 31

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025

Patient Care Online·Aug 1

Extension trial demonstrates long-term benefit for Lilly Alzheimer's drug | News

European Pharmaceutical Review·Jul 30

View original report at Neurology Today ↗

Fetching the latest headlines…

Extension of Lecanemab Trial Shows Continued Benefit

Full coverage

Updates on Blarcamesine and Lecanemab for Alzheimer Disease From AD/PD 2026

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

Lecanemab Shows Sustained Benefit at 4 Years in Early Alzheimer Disease: AAIC 2025

Roche’s Alzheimer’s therapy shows continued benefit

Huntington’s Disease Therapy Shows Sustained Clinical Benefit at 36 Months

Lecanemab Preserves Memory Over 4 Years in Early AD

Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease

Extension trial demonstrates long-term benefit for Lilly Alzheimer's drug | News